Table 1 Patient characteristics of the analyzed patient cohort and distribution of Activin high and low expressing primary tumors. Significance calculated by X2-Test
From: Prognostic impact of activin subunit inhibin beta A in gastric and esophageal adenocarcinomas
All | Activin | ||||||
|---|---|---|---|---|---|---|---|
Total | low. | high. | p | ||||
n | (%) | n | (%) | n | (%) | ||
Gender | |||||||
Female | 100 | (36.1) | 78 | 78.0 | 22 | 22.0 | 0.298 |
Male | 177 | (63.9) | 128 | 72.3 | 49 | 27.7 | |
Age Group | |||||||
< 65 years | 156 | (56.3) | 110 | 70.5 | 46 | 29.5 | 0.095 |
> = 65 years | 121 | (43.7) | 96 | 79.3 | 25 | 20.7 | |
Localization | |||||||
Gastric Cancer | 230 | (83.0) | 171 | 74.3 | 59 | 25.7 | 0.986 |
AEG | 47 | (17.0) | 35 | 74.5 | 12 | 25.5 | |
Tumor stage | |||||||
T1 | 38 | (13.7) | 21 | 55.3 | 17 | 44.7 | 0.041 |
T2 | 105 | (37.9) | 78 | 74.3 | 27 | 25.7 | |
T3 | 102 | (36.8) | 80 | 78.4 | 22 | 21.6 | |
T4 | 31 | (11.2) | 26 | 83.9 | 5 | 16.1 | |
unspecified | 1 | (0.4) | 0 | 0.0 | 1 | 100.0 | |
Node Stage | |||||||
N0 | 71 | (25.6) | 45 | 63.4 | 26 | 36.6 | 0.014 |
N+ | 206 | (74.4) | 161 | 78.2 | 45 | 21.8 | |
Distante Metastasis | |||||||
M0 | 196 | (70.8) | 136 | 69.4 | 60 | 30.6 | 0.003 |
M1 | 81 | (29.2) | 70 | 86.4 | 11 | 13.6 | |
Lymphatic vessel invasion | |||||||
L0 | 92 | (33.2) | 63 | 68.5 | 29 | 31.5 | 0.137 |
L1 | 165 | (59.6) | 127 | 77.0 | 38 | 23.0 | |
unspecified | 20 | (7.2) | – | – | |||
Vein invasion | |||||||
V0 | 164 | (59.2) | 116 | 70.7 | 48 | 29.3 | 0.107 |
V1 | 90 | (32.5) | 72 | 80.0 | 18 | 20.0 | |
unspecified | 23 | (8.3) | – | – | |||
Grading | |||||||
G1 | 1 | (0.4) | 0 | 0.0 | 1 | 100.0 | 0.35 |
G2 | 73 | (26.4) | 48 | 64.9 | 26 | 35.1 | |
G3 | 200 | (72.2) | 157 | 78.5 | 43 | 21.5 | |
unspecified | 3 | (1.1) | |||||
Lauren Classification | |||||||
Intestinal | 98 | (35.4) | 65 | 66.3 | 33 | 33.7 | 0.114 |
Diffuse | 139 | (50.2) | 108 | 77.7 | 31 | 22.3 | |
Mixed | 37 | (13.4) | 31 | 83.8 | 6 | 16.2 | |
unspecified | 3 | (1.1) | |||||
Ming Classification | |||||||
expansive | 109 | (39.4) | 72 | 66.1 | 37 | 33.9 | 0.034 |
infiltrative | 165 | (59.6) | 132 | 80.0 | 33 | 20.0 | |
unspecified | 3 | (1.1) | |||||
MMR | |||||||
proficient | 240 | (86.6) | 178 | 74.2 | 62 | 25.8 | 0.997 |
deficient | 31 | (11.2) | 23 | 74.2 | 8 | 25.8 | |
unspecified | 6 | (2.2) | – | – | – | – | |
CD3 | |||||||
low | 137 | (49.5) | 105 | 76.6 | 32 | 23.4 | 0.691 |
high | 118 | (42.6) | 85 | 72.0 | 33 | 28.0 | |
unspecified | 22 | (7.9) | – | – | – | – | |
CD4 | |||||||
low | 147 | (60.0) | 120 | 81.6 | 27 | 18.4 | 0.009 |
high | 98 | (35.4) | 63 | 64.3 | 35 | 35.7 | |
unspecified | 32 | (11.6) | – | – | – | – | |
CD8 | |||||||
low | 134 | (48.4) | 106 | 79.1 | 28 | 20.9 | 0.217 |
high | 120 | (43.3) | 84 | 70.0 | 36 | 30.0 | |
unspecified | 23 | (8.3) | – | – | – | – | |
PD-L1 in lymphocytes | |||||||
negative | 182 | (65.7) | 141 | 77.5 | 41 | 22.5 | 0.065 |
positive | 81 | (29.2) | 54 | 66.7 | 27 | 33.3 | |
unspecified | 11 | (4.0) | – | – | – | – | |
PD-L1 in tumor cells | |||||||
negative | 245 | (88.4) | 185 | 75.5 | 60 | 24.5 | 0.062 |
positive | 18 | (6.5) | 10 | 55.6 | 8 | 44.4 | |
unspecified | 11 | (4.0) | – | – | – | – | |
PD-1 in lymphocytes | |||||||
negative | 112 | (40.4) | 90 | 80.4 | 22 | 19.6 | 0.051 |
Positive | 145 | (52.3) | 101 | 69.7 | 44 | 30.3 | |
unspecified | 20 | (7.2) | – | – | – | – | |
PD-1 in tumor cells | |||||||
negative | 259 | (93.5) | 192 | 74.1 | 67 | 25.9 | – |
positive | 0 | (0.0) | 0 | 0 | 0 | 0 | |
unspecified | 18 | (6.5) | – | – | – | – | |